Welcome to our dedicated page for Shattuck Labs news (Ticker: STTK), a resource for investors and traders seeking the latest updates and insights on Shattuck Labs stock.
Shattuck Labs, Inc. develops monoclonal and bispecific DR3-blocking antibodies for inflammatory and immune-mediated diseases. The company’s news centers on SL-325, a Death Receptor 3 antibody targeting the DR3/TL1A pathway, with emphasis on clinical development in inflammatory bowel disease and related immune-mediated conditions.
Recurring updates also cover quarterly financial results, cash and capital-structure disclosures, investor conference participation, inducement equity awards, and governance matters tied to Shattuck’s Nasdaq-listed common stock.
Shattuck Labs announced the successful closing of its upsized initial public offering, consisting of 13,664,704 shares at $17.00 each, garnering approximately $232.3 million in gross proceeds. The offering included the full exercise of underwriters' options for an additional 1,782,352 shares. All shares were offered by Shattuck, with trading on Nasdaq under the symbol STTK commencing on October 9, 2020. The company focuses on developing bi-functional fusion proteins for cancer and autoimmune disease treatments, with key programs currently in Phase 1 trials.
Shattuck Labs has announced the pricing of its upsized initial public offering, offering 11,882,352 shares of common stock at $17.00 each, aiming for gross proceeds of approximately $202 million. The shares will commence trading on Nasdaq under the symbol STTK on October 9, 2020. An additional 1,782,352 shares may be purchased by underwriters within 30 days of the offering. The offering is set to close on October 14, 2020, subject to customary conditions. Citigroup, Cowen, and Evercore ISI are joint book-running managers for this offering.